These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34667922)

  • 1. The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Res Pract Thromb Haemost; 2021 Oct; 5(7):e12601. PubMed ID: 34667922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand.
    Álvarez-Román MT; Shapiro AD; Ragni MV; Palmborg H; Bystrická L; Szamosi J; Casiano S; Chambost H
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102163. PubMed ID: 37720484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of physicians' treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries.
    van der Sluijs M; Huyghe N; Wood C; Tawil S
    Curr Med Res Opin; 2022 Jan; 38(1):65-73. PubMed ID: 34634979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.
    Shrestha A; Su J; Li N; Barnowski C; Jain N; Everson K; Jena AB; Batt K
    Res Pract Thromb Haemost; 2021 Jan; 5(1):94-103. PubMed ID: 33537533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B:
    Astermark J; Hermans C; Ezzalfani M; Sidhom A; Barbier S; Kragh N; Falk A; Eriksson D
    Ther Adv Hematol; 2023; 14():20406207231170701. PubMed ID: 37283819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
    Lehtinen AE; Baghaei F; Astermark J; Holme PA
    Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
    J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life.
    O'Donovan M; Quinn E; Johnston K; Singleton E; Benson J; O'Mahony B; Noone D; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM; Mahlangu J
    Res Pract Thromb Haemost; 2021 Oct; 5(7):e12602. PubMed ID: 34667923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies.
    Wyrwich KW; Krishnan S; Auguste P; Poon JL; von Maltzahn R; Yu R; Pierce GF; Mei B; Mahlangu J; von Mackensen S
    Haemophilia; 2016 Nov; 22(6):866-872. PubMed ID: 27385432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries.
    Funding E; Lowe G; Poulsen LH; Shapiro S; Oldenburg J; Eriksson D; Falk A; Rich C
    Adv Ther; 2023 Sep; 40(9):3770-3783. PubMed ID: 37351812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies.
    Chowdary P; Holmström M; Mahlangu JN; Ozelo MC; Pabinger I; Pasi KJ; Ragni MV; Shapiro A; Barnowski C; Lethagen S
    Res Pract Thromb Haemost; 2022 Jul; 6(5):e12760. PubMed ID: 35910942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires.
    Astermark J; Hermans C; Ezzalfani M; Aballéa S; Santagostino E; Hakimi Z; Nazir J
    Haemophilia; 2022 Jan; 28(1):18-26. PubMed ID: 34761474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpreting important health-related quality of life change using the Haem-A-QoL.
    Wyrwich KW; Krishnan S; Poon JL; Auguste P; von Maltzahn R; Yu R; von Mackensen S
    Haemophilia; 2015 Sep; 21(5):578-84. PubMed ID: 25828456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement properties of the Haem-A-QoL in haemophilia clinical trials.
    von Mackensen S; Eldar-Lissai A; Auguste P; Krishnan S; von Maltzahn R; Yu R; Wyrwich KW
    Haemophilia; 2017 May; 23(3):383-391. PubMed ID: 28026074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Analysis of Dispensed International Units of Coagulation Factor VIII and Resultant Expenditures for Hemophilia A Patients: A Comparison Between Standard Half-Life and Extended Half-Life Products.
    Chhabra A; Fogarty PF; Tortella BJ; Spurden D; Alvir J; McDonald M; Hodge J; Pleil AM
    Manag Care; 2018 Oct; 27(10):39-50. PubMed ID: 30309448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.